180 related articles for article (PubMed ID: 32510137)
1. The SGLT2 inhibitor canagliflozin suppresses lipid synthesis and interleukin-1 beta in ApoE deficient mice.
Day EA; Ford RJ; Lu JH; Lu R; Lundenberg L; Desjardins EM; Green AE; Lally JSV; Schertzer JD; Steinberg GR
Biochem J; 2020 Jun; 477(12):2347-2361. PubMed ID: 32510137
[TBL] [Abstract][Full Text] [Related]
2. The Na+/Glucose Cotransporter Inhibitor Canagliflozin Activates AMPK by Inhibiting Mitochondrial Function and Increasing Cellular AMP Levels.
Hawley SA; Ford RJ; Smith BK; Gowans GJ; Mancini SJ; Pitt RD; Day EA; Salt IP; Steinberg GR; Hardie DG
Diabetes; 2016 Sep; 65(9):2784-94. PubMed ID: 27381369
[TBL] [Abstract][Full Text] [Related]
3. The SGLT2 Inhibitor Canagliflozin Reduces Atherosclerosis by Enhancing Macrophage Autophagy.
Chen H; Teng D; Xu B; Wang C; Wang H; Jia W; Gong L; Dong H; Zhong L; Yang J
J Cardiovasc Transl Res; 2023 Oct; 16(5):999-1009. PubMed ID: 37126209
[TBL] [Abstract][Full Text] [Related]
4. Canagliflozin inhibits interleukin-1β-stimulated cytokine and chemokine secretion in vascular endothelial cells by AMP-activated protein kinase-dependent and -independent mechanisms.
Mancini SJ; Boyd D; Katwan OJ; Strembitska A; Almabrouk TA; Kennedy S; Palmer TM; Salt IP
Sci Rep; 2018 Mar; 8(1):5276. PubMed ID: 29588466
[TBL] [Abstract][Full Text] [Related]
5. Canagliflozin attenuates the progression of atherosclerosis and inflammation process in APOE knockout mice.
Nasiri-Ansari Ν; Dimitriadis GK; Agrogiannis G; Perrea D; Kostakis ID; Kaltsas G; Papavassiliou AG; Randeva HS; Kassi E
Cardiovasc Diabetol; 2018 Jul; 17(1):106. PubMed ID: 30049285
[TBL] [Abstract][Full Text] [Related]
6. Xanthohumol ameliorates atherosclerotic plaque formation, hypercholesterolemia, and hepatic steatosis in ApoE-deficient mice.
Doddapattar P; Radović B; Patankar JV; Obrowsky S; Jandl K; Nusshold C; Kolb D; Vujić N; Doshi L; Chandak PG; Goeritzer M; Ahammer H; Hoefler G; Sattler W; Kratky D
Mol Nutr Food Res; 2013 Oct; 57(10):1718-28. PubMed ID: 23650230
[TBL] [Abstract][Full Text] [Related]
7. SGLT2 inhibition reprograms systemic metabolism via FGF21-dependent and -independent mechanisms.
Osataphan S; Macchi C; Singhal G; Chimene-Weiss J; Sales V; Kozuka C; Dreyfuss JM; Pan H; Tangcharoenpaisan Y; Morningstar J; Gerszten R; Patti ME
JCI Insight; 2019 Mar; 4(5):. PubMed ID: 30843877
[TBL] [Abstract][Full Text] [Related]
8. Empagliflozin inhibits macrophage inflammation through AMPK signaling pathway and plays an anti-atherosclerosis role.
Fu J; Xu H; Wu F; Tu Q; Dong X; Xie H; Cao Z
Int J Cardiol; 2022 Nov; 367():56-62. PubMed ID: 35931206
[TBL] [Abstract][Full Text] [Related]
9. Canagliflozin, a sodium glucose cotransporter 2 inhibitor, attenuates obesity-induced inflammation in the nodose ganglion, hypothalamus, and skeletal muscle of mice.
Naznin F; Sakoda H; Okada T; Tsubouchi H; Waise TM; Arakawa K; Nakazato M
Eur J Pharmacol; 2017 Jan; 794():37-44. PubMed ID: 27876617
[TBL] [Abstract][Full Text] [Related]
10. Sodium-glucose co-transporter-2 (SGLT-2) inhibition reduces glucose uptake to induce breast cancer cell growth arrest through AMPK/mTOR pathway.
Zhou J; Zhu J; Yu SJ; Ma HL; Chen J; Ding XF; Chen G; Liang Y; Zhang Q
Biomed Pharmacother; 2020 Dec; 132():110821. PubMed ID: 33068934
[TBL] [Abstract][Full Text] [Related]
11. The diabetes medication Canagliflozin reduces cancer cell proliferation by inhibiting mitochondrial complex-I supported respiration.
Villani LA; Smith BK; Marcinko K; Ford RJ; Broadfield LA; Green AE; Houde VP; Muti P; Tsakiridis T; Steinberg GR
Mol Metab; 2016 Oct; 5(10):1048-1056. PubMed ID: 27689018
[TBL] [Abstract][Full Text] [Related]
12. Canagliflozin ameliorates obesity by improving mitochondrial function and fatty acid oxidation via PPARα in vivo and in vitro.
Wei D; Liao L; Wang H; Zhang W; Wang T; Xu Z
Life Sci; 2020 Apr; 247():117414. PubMed ID: 32035928
[TBL] [Abstract][Full Text] [Related]
13. FGF21 does not require adipocyte AMP-activated protein kinase (AMPK) or the phosphorylation of acetyl-CoA carboxylase (ACC) to mediate improvements in whole-body glucose homeostasis.
Mottillo EP; Desjardins EM; Fritzen AM; Zou VZ; Crane JD; Yabut JM; Kiens B; Erion DM; Lanba A; Granneman JG; Talukdar S; Steinberg GR
Mol Metab; 2017 Jun; 6(6):471-481. PubMed ID: 28580278
[TBL] [Abstract][Full Text] [Related]
14. Canagliflozin Prevents Diabetes-Induced Vascular Dysfunction in ApoE-Deficient Mice.
Rahadian A; Fukuda D; Salim HM; Yagi S; Kusunose K; Yamada H; Soeki T; Sata M
J Atheroscler Thromb; 2020 Nov; 27(11):1141-1151. PubMed ID: 32101837
[TBL] [Abstract][Full Text] [Related]
15. 6-Gingerol Ameliorates Behavioral Changes and Atherosclerotic Lesions in ApoE
Wang S; Tian M; Yang R; Jing Y; Chen W; Wang J; Zheng X; Wang F
Cardiovasc Toxicol; 2018 Oct; 18(5):420-430. PubMed ID: 29605868
[TBL] [Abstract][Full Text] [Related]
16. Canagliflozin Attenuates Hepatic Steatosis and Atherosclerosis Progression in Western Diet-Fed ApoE-Knockout Mice.
Zuo Q; Zhang G; He L; Ma S; Ma H; Zhai J; Wang Z; Zhang T; Wang Y; Guo Y
Drug Des Devel Ther; 2022; 16():4161-4177. PubMed ID: 36510490
[TBL] [Abstract][Full Text] [Related]
17. Canagliflozin regulates metabolic reprogramming in diabetic kidney disease by inducing fasting-like and aestivation-like metabolic patterns.
Shao M; Chen D; Wang Q; Guo F; Wei F; Zhang W; Gan T; Luo Y; Fan X; Du P; Liu Y; Ma X; Ren G; Song Y; Zhao Y; Qin G
Diabetologia; 2024 Apr; 67(4):738-754. PubMed ID: 38236410
[TBL] [Abstract][Full Text] [Related]
18. Differential effect of canagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, on slow and fast skeletal muscles from nondiabetic mice.
Otsuka H; Yokomizo H; Nakamura S; Izumi Y; Takahashi M; Obara S; Nakao M; Ikeda Y; Sato N; Sakamoto R; Miyachi Y; Miyazawa T; Bamba T; Ogawa Y
Biochem J; 2022 Feb; 479(3):425-444. PubMed ID: 35048967
[TBL] [Abstract][Full Text] [Related]
19. Canagliflozin Inhibits Glioblastoma Growth and Proliferation by Activating AMPK.
Shoda K; Tsuji S; Nakamura S; Egashira Y; Enomoto Y; Nakayama N; Shimazawa M; Iwama T; Hara H
Cell Mol Neurobiol; 2023 Mar; 43(2):879-892. PubMed ID: 35435536
[TBL] [Abstract][Full Text] [Related]
20. Amelioration of diet-induced metabolic syndrome and fatty liver with sitagliptin via regulation of adipose tissue inflammation and hepatic Adiponectin/AMPK levels in mice.
Prakash S; Rai U; Kosuru R; Tiwari V; Singh S
Biochimie; 2020 Jan; 168():198-209. PubMed ID: 31715215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
